WVE — Wave Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $1.18bn
- $995.30m
- $108.30m
Annual income statement for Wave Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 20.1 | 41 | 3.65 | 113 | 108 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 173 | 168 | 166 | 181 | 219 |
| Operating Profit | -153 | -127 | -163 | -68 | -110 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -151 | -122 | -161 | -58.2 | -97 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -150 | -122 | -162 | -57.5 | -97 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -150 | -122 | -162 | -57.5 | -97 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -150 | -122 | -162 | -57.5 | -97 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.82 | -2.36 | -2.05 | -0.542 | -0.702 |